Format

Send to

Choose Destination
See comment in PubMed Commons below
Infect Dis Obstet Gynecol. 1998;6(5):197-203.

Zidovudine.

Author information

1
Department of Obstetrics, Gynecology, and Reproductive Sciences, Mount Sinai Medical Center, New York, NY 10029-6574, USA. rsperling@smtplink.mssm.edu

Abstract

Zidovudine was the first agent approved for treatment of HIV disease, and since its widespread availability in 1987, the pharmacokinetic disposition and clinical effects of ZDV have been extensively evaluated. In addition to its utility as a component of a multidrug combination regimen for the treatment of adult and pediatric HIV-1 infection, it is the only agent approved by the FDA for the prevention of mother-to-child HIV-1 transmission. The effectiveness of ZDV for the prevention of mother-to-child HIV-1 transmission has been demonstrated in several studies. The optimal time during gestation to initiate ZDV therapy and the relative importance of the intrapartum and newborn components is the focus of both current interventional and observational studies. Until more information is available from these trials, the combined maternal/newborn ZDV regimen studied in ACTG 076 remains the recommended treatment regimen of choice in the United States.

PMID:
9894173
PMCID:
PMC1784811
DOI:
10.1155/S1064744998000404
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Hindawi Publishing Corporation Icon for PubMed Central
    Loading ...
    Support Center